HyperMed Imaging, Inc. announced the company’s HyperView Imaging System to customers in the United States.
The HyperView System is FDA cleared, handheld, battery operated, non-invasive, and portable diagnostic imaging device that is used to assess tissue oxygenation without contacting the patient and without the need for injectable contrast. The system uses proprietary technology to capture color-coded images containing data that provides the clinician critical information such as oxyhemoglobin levels (Oxy), deoxyhemoglobin levels (Deoxy), and oxygen saturation (O2Sat) in superficial tissue. Such information may assist clinicians when determining if a patient has adequate blood perfusion to heal a wound or maintain healthy tissue. Understanding both arterial and venous sufficiency in the surface tissue may enable clinicians to make more informed decisions regarding when to intervene.
The HyperView system also helps document perfusion levels before and after vascular interventional procedures such as: peripheral bypass, stent placement, or balloon angioplasty.
HyperMed’s Vice President of Sales, Annette Plishka, comments, “We are pleased to offer the new HyperView system to our customers in the USA. There are many important applications for this exciting new diagnostic imaging device in wound care, vascular intervention and reconstructive surgery.” HyperMed’s President and CEO, Mark Darty added, “Early market feedback from customers has confirmed that HyperView is a game changer. It is a product poised to impact a number of important market segments. The low cost, speed, portability, ease of use and high-quality data and imagery provide clinicians a new class of tool to rapidly assess perfusion and locate ischemic tissue. This information helps caregivers better understand potential circulatory compromise and allow more informed treatment of complications of vascular disease and diabetes.”
HyperMed will be present at the Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV on October 20 – 22, 2017 where product demonstrations will be available at exhibit booth #443.